‘A catalyst for revolution’: Launch of Thrive looks to safeguard public health

FHS
July 23, 2024
9:48 am

Brisbane is positioned to become the global hub for healthy buildings with today’s launch of the ARC Training Centre for Advanced Building Systems against Airborne Infection Transmission (Thrive).

POINT’s prostate cancer trial meets primary endpoint as Lilly’s offer looms – Pharmaceutical Technology

Share this article Credit: Michael Vi / Shutterstock.com US-based Lantheus and POINT Biopharma have announced positive topline data from the Phase III trial investigating prostate

December 19, 2023

Investigating the efficacy and safety of existing drugs in patients with rare immune diseases

This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.

April 23, 2024

Verona Ohtuvayre set to transform US COPD exacerbator market

The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is tailored towards patients with moderate

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.